RecruitingPhase 2NCT06397911

Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Pharmacokinetics, and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis

Sponsor

Oneness Biotech Co., Ltd.

Enrollment

114 participants

Start Date

Aug 8, 2024

Study Type

INTERVENTIONAL

Conditions

Atopic Dermatitis

Summary

This is a randomized, placebo-controlled and double-blind study to evaluate the efficacy, pharmacokinetics, and Safety of repeat subcutaneous doses of FB825 in adults with moderate-to-severe atopic dermatitis.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called FB825 and a drug called Placebo for people with atopic dermatitis. The study is currently recruiting participants at 16 locations. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGFB825

The study treatment will be administered as 5 SC doses in total 12 weeks

DRUGPlacebo

The study treatment will be administered as 5 SC doses in total 12 weeks

Locations(16)

First OC Dermatology

Fountain Valley, California, United States

Center for Dermatology Clinical Research, Inc.

Fremont, California, United States

California Allergy and Asthma Medical Group

Los Angeles, California, United States

University of California, Davis Health, Department of Dermatology

Sacramento, California, United States

UT Health Science Houston

Bellaire, Texas, United States

Center for Clinical Studies

Webster, Texas, United States

Kaohsiung Chang Gung Memorial Hospital

Kaohsiung City, Taiwan

Kaohsiung Veterans General Hospital

Kaohsiung City, Taiwan

Linkou Chang Gung Memorial Hospital

New Taipei City, Taiwan

Taipei Medical University-Shuang Ho Hospital

New Taipei City, Taiwan

China Medical University Hospital

Taichung, Taiwan

National Cheng Kung University Hospital

Tainan, Taiwan

National Taiwan University Hospital

Taipei, Taiwan

Taipei Mackay Memorial Hospital

Taipei, Taiwan

Taipei Veterans General Hospital

Taipei, Taiwan

Tri-Service General Hospital

Taipei, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06397911

Related Trials

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

NCT072629831 location

Studies of Skin Microbes in Healthy People and in People With Skin Conditions

NCT006058781 location

Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases

NCT065994111 location

Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares

NCT076458204 locations

A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

NCT0700342556 locations